# Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds

Study · id `cardio:ct-nct07223892` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07223892](<https://clinicaltrials.gov/study/NCT07223892>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07223892

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT07223892. Randomized; single masking; primary purpose treatment. Start 2026-01-01 (anticipated); primary completion 2028-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT07223892, source copy `cardio:ctgov-nct07223892-2025-11-06`, retrieved 2026-10-26)
- Planned start: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT07223892, source copy `cardio:ctgov-nct07223892-2025-11-06`, retrieved 2026-10-26)
- Primary completion: 2028-01 (anticipated) (ClinicalTrials.gov record NCT07223892, source copy `cardio:ctgov-nct07223892-2025-11-06`, retrieved 2026-10-26)
- Completion: 2028-03 (anticipated) (ClinicalTrials.gov record NCT07223892, source copy `cardio:ctgov-nct07223892-2025-11-06`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07223892-2025-11-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds
- Condition: Chronic Wounds
- Condition: Venous Leg Ulcers (VLUs)
- Condition: Diabetic Foot Ulcers (DFUs)
- Condition: Arterial Ulcers
- Condition: Pressure Ulcers
- Condition: Burn Wounds
- Condition: Trauma Wounds
- Condition: Surgical Wounds
- Intervention (Biological): Amniotic Tissue Allograft
- Lead sponsor: Bardia Anvar
- Lead sponsor class: INDUSTRY
- Collaborator: Carbon Life Sciences
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 8dcb1048383327e0d843d529e4fe787795aa6eac8d30f13e1d3a7db0c25943d8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
